First-line treatment with polatuzumab vedotin improves efficacy and survival in newly diagnosed patients with advanced diffuse large B-cell lymphoma: a multicentre retrospective analysis
Pola plus chemotherapy demonstrates superior efficacy and may prolong survival in patients with newly diagnosed advanced or high-risk DLBCL. However, it does not mitigate the unfavorable prognosis in patients with high P53 expression.
Authors
- Xuliang Shen (ORCID: https://orcid.org/0000-0002-9349-7591)
- Xiaosu Zhao (ORCID: https://orcid.org/0000-0001-7749-8087)
- Ye Geng (ORCID: https://orcid.org/0009-0000-5182-7719)
- Jinghe Lang (ORCID: https://orcid.org/0000-0002-4755-9894)
- Cai‐Xia Zhang (ORCID: https://orcid.org/0000-0001-9671-9412)
- Yaru Wang (ORCID: https://orcid.org/0000-0003-1734-8487)
- Qi Liu (ORCID: https://orcid.org/0009-0002-2468-4972)
- Si-Jun Bai
- Yunfei Shi (ORCID: https://orcid.org/0000-0002-0417-5727)
- Jianxia He (ORCID: https://orcid.org/0000-0003-0138-0570)
- Yi-Nan Gao
- Wei-Wei Tian
Institutions
- Shanxi Medical University (CN)
- Changzhi Medical College (CN)
- Zoucheng People's Hospital (CN)
- Second Hospital of Shanxi Medical University (CN)
- Shanxi Academy of Medical Sciences (CN)
- Shanxi Provincial People’s Hospital (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1080/07853890.2025.2566871
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00